News | November 15, 2006

Long-Term Data Assesses Prostate Cancer Treatment Side Effects

New research findings show men have fewer long-term gastrointestinal side effects with intensity-modulated radiation therapy (IMRT) than with three-dimensional conformal radiation therapy (3D CRT) for prostate cancer treatment, despite the higher doses of radiation used in the IMRT group.
Both techniques allow precise targeting of the cancer with multiple X-ray beams, but IMRT allows physicians to modulate the radiation dose intensity with far smaller radiation beams. Thus, doses of radiation to the bladder and rectum can be limited. Reducing radiation exposure to healthy normal tissue and other vital organs helps prevent once common side effects such as urinary frequency and diarrhea.
In the study, researchers analyzed data collected prospectively from 1,417 patients treated at Fox Chase Cancer Center in Philadelphia. Of these, 928 men were treated with 3D CRT (median follow-up of 63.3 months) and 489 men with IMRT (median follow-up of 29.9 months). The IMRT patients received higher doses of radiation.
"There were no differences in the reporting of acute gastrointestinal or genitourinary side effects for the two treatment modalities," explained Alexander Kirichenko, M.D., Ph.D., lead author of the study and a clinical fellow at Fox Chase at the time of the analysis. "However, as the data are beginning to mature, we're seeing more long-term gastrointestinal side effects in the men treated with 3D CRT."
Kirichenko concluded, "Despite the specific findings pertaining to 3D CRT technique and the gastrointestinal side effects, men treated with either modality have acceptable rates of side effects at this point in our analysis particularly when compared to data from surgical outcomes."

Related Content

Bay Labs Announces New Data on EchoGPS, AutoEF AI Software at ACC.19
News | Cardiovascular Ultrasound | March 15, 2019
Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the...
Canon Medical Systems introduces 33 MHz Ultra-High Frequency Ultrasound Transducer
News | Ultrasound Imaging | March 01, 2019
March 1, 2019 — Expanding its advanced, high-performing Aplio i-series...
Philips Launches Latest Iteration of IntelliSpace Cardiovascular at HIMSS 2019
Technology | Cardiac PACS | February 13, 2019
Philips announced the launch of IntelliSpace Cardiovascular 4.1, its next-generation cardiovascular image and...
An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. 

Feature | Ultrasound Imaging | February 07, 2019 | Dave Fornell, Editor
Here is a list of six key trends in ul...
ASE Releases Guidelines for Transesophageal Echo in Congenital Heart Disease
News | Ultrasound Transesophageal echo (TEE) | February 05, 2019
February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensi
ASE Releases New Guide to Performing Comprehensive Transthoracic Echo Exams
News | Cardiovascular Ultrasound | January 21, 2019
January 21, 2019 – Medical experts have released “...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...